The Guangzhou Municipal Industry and Information Technology Bureau has unveiled the first batch of innovative drugs and medical devices included in the city’s list, with 24 products making the shortlist. This initiative is aimed at promoting local innovation and development within the pharmaceutical and medical device sectors.
Among the notable products selected is Akeso Biopharma’s (HKG: 9926) cadonilimab, a bispecific antibody (BsAb) drug candidate that targets both programmed death-1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). This potential first-in-class therapy has shown promise in treating various cancers.
Bio-Thera Solutions (SHA: 688177) has also made the list with its biosimilars of bevacizumab, tocilizumab, and adalimumab, offering patients access to more affordable versions of these critical biologic drugs.
BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) is represented on the list with its programmed death-1 (PD-1) inhibitor Tevimbra (tislelizumab), which has been approved for use in various cancer treatments, further expanding the city’s portfolio of innovative oncology drugs.
Yipinhong Pharmacy Co., Ltd (SHE: 300723) contributes to the list with its modified Category 2.2 drug amlodipine dry suspension, a significant advancement in the treatment of hypertension.
The selection of these products by the Guangzhou Municipal Industry and Information Technology Bureau highlights the city’s commitment to fostering a robust ecosystem for medical innovation and enhancing the accessibility of cutting-edge therapies for patients.- Flcube.com
